Four-Day Bravo pH Capsule Monitoring With and Without Proton Pump Inhibitor Therapy  Ikuo Hirano, Qing Zhang, John E. Pandolfino, Peter J. Kahrilas  Clinical Gastroenterology and Hepatology  Volume 3, Issue 11, Pages 1083-1088 (November 2005) DOI: 10.1016/S1542-3565(05)00529-X Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Percent time of pH less than 4 for each day of the 4-day study. A significant reduction in distal esophageal acid exposure occurred within the first day of administration of rabeprazole (day 2) and was maintained throughout the remainder of the recording period. Only 1 patient (6%) failed to normalize acid exposure levels during the treatment phase. The horizontal bars represent the median acid exposure for each day. *Significance at the P < .005 level. Clinical Gastroenterology and Hepatology 2005 3, 1083-1088DOI: (10.1016/S1542-3565(05)00529-X) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Representative 96-hour Bravo pH tracing from a patient with significant GERD on day 1. The shaded regions represent supine periods. Initial esophageal exposure was 10.2% on day 1 and showed an upright reflux pattern. After the administration of rabeprazole at 20 mg orally twice a day, the acid exposure decreased to 2% on day 2, .7% on day 3, and .3% on day 4. Clinical Gastroenterology and Hepatology 2005 3, 1083-1088DOI: (10.1016/S1542-3565(05)00529-X) Copyright © 2005 American Gastroenterological Association Terms and Conditions